Apnimed raises $192M in IPO for sleep apnea pill

Apnimed, a biotech startup developing a pill for sleep apnea, has successfully raised $192 million in an upsized Initial Public Offering (IPO). The company's shares are set to trade on the Nasdaq, with the IPO valuing Apnimed at over $600 million. This funding comes as Apnimed aims to provide an alternative to the widely disliked CPAP machines, targeting the significant portion of sleep apnea patients who are diagnosed but untreated. AI

RANK_REASON Significant funding event for a biotech company with a novel therapeutic approach. [lever_c_demoted from significant: ic=1 ai=0.0]

Read on Forbes — Innovation →

• Alpha Wave Global
• Apnimed
• Eli Lilly and Company
• Forbes
• Harvard University
• Kevin Lindsay
• Larry Miller
• Longboard Pharmaceuticals
• Luigi Taranto Monetemurro
• Lundbeck
• Morningside Group
• Nasdaq
• Sectoral Asset Management

• funding
• product

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →